Formestane: an effective first-line endocrine treatment for advanced breast cancer
Formestane, a new selective aromatase inhibitor devoid of severe side-effects, has been shown to be active in patients with advanced breast cancer. To investigate the clinical activity and endocrinological effects of formestane as a first-line treatment, 52 patients were administered two different d...
Saved in:
Published in | Journal of cancer research and clinical oncology Vol. 121; no. 6; p. 378 |
---|---|
Main Authors | , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Germany
01.06.1995
|
Subjects | |
Online Access | Get more information |
Cover
Loading…
Abstract | Formestane, a new selective aromatase inhibitor devoid of severe side-effects, has been shown to be active in patients with advanced breast cancer. To investigate the clinical activity and endocrinological effects of formestane as a first-line treatment, 52 patients were administered two different doses: 24 received 250 mg formestane and 28 received 500 mg formestane i.m. fortnightly. All of the patients had a performance status of 2 or less (ECOG scale), 34 (65%) had a disease-free interval of at least 2 years and 21 (40%) were both oestrogen-receptor- and progesterone-receptor-positive; 20 patients received hormone and 13, received chemotherapeutical adjuvant treatment. Objective responses were obtained in 8 patients in the 250-mg group (33%; 95% CI: 14%-52%) and in 13 patients in the 500-mg group (46%; 95% CI: 28%-64%). The median response duration in the two groups was respectively 11 and 12 months. E2 serum levels of oestradiol had significantly (P < 0.001) decreased to more than 40% below the baseline value in both groups after 15 days of treatment, and remained unchanged thereafter. Local and systemic tolerability was satisfactory. We conclude that formestane is an effective and well-tolerated agent in previously untreated patients, and that these results should be confirmed by further studies. |
---|---|
AbstractList | Formestane, a new selective aromatase inhibitor devoid of severe side-effects, has been shown to be active in patients with advanced breast cancer. To investigate the clinical activity and endocrinological effects of formestane as a first-line treatment, 52 patients were administered two different doses: 24 received 250 mg formestane and 28 received 500 mg formestane i.m. fortnightly. All of the patients had a performance status of 2 or less (ECOG scale), 34 (65%) had a disease-free interval of at least 2 years and 21 (40%) were both oestrogen-receptor- and progesterone-receptor-positive; 20 patients received hormone and 13, received chemotherapeutical adjuvant treatment. Objective responses were obtained in 8 patients in the 250-mg group (33%; 95% CI: 14%-52%) and in 13 patients in the 500-mg group (46%; 95% CI: 28%-64%). The median response duration in the two groups was respectively 11 and 12 months. E2 serum levels of oestradiol had significantly (P < 0.001) decreased to more than 40% below the baseline value in both groups after 15 days of treatment, and remained unchanged thereafter. Local and systemic tolerability was satisfactory. We conclude that formestane is an effective and well-tolerated agent in previously untreated patients, and that these results should be confirmed by further studies. |
Author | Bichisao, E Buzzoni, R Biasi, G Zilembo, N Bono, A Laffranchi, A Bajetta, E Dolci, S Vicario, G Noberasco, C |
Author_xml | – sequence: 1 givenname: N surname: Zilembo fullname: Zilembo, N organization: Division of Medical Oncology B, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy – sequence: 2 givenname: E surname: Bajetta fullname: Bajetta, E – sequence: 3 givenname: C surname: Noberasco fullname: Noberasco, C – sequence: 4 givenname: R surname: Buzzoni fullname: Buzzoni, R – sequence: 5 givenname: G surname: Vicario fullname: Vicario, G – sequence: 6 givenname: A surname: Bono fullname: Bono, A – sequence: 7 givenname: A surname: Laffranchi fullname: Laffranchi, A – sequence: 8 givenname: G surname: Biasi fullname: Biasi, G – sequence: 9 givenname: S surname: Dolci fullname: Dolci, S – sequence: 10 givenname: E surname: Bichisao fullname: Bichisao, E |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/7797604$$D View this record in MEDLINE/PubMed |
BookMark | eNotj01LAzEURbOo1La6cS_kD4wmL18Td1ocFQqC6LpkkhcY6WRKEgv-e1vs6t5zFhfukszSlJCQG87uOGPm_qljHEBpCzOyYNzwRgHXl2RZyjc7sjIwJ3NjrNFMLshHN-URS3UJH6hLFGNEX4cD0jjkUpvdkJBiCpPPp1YzujpiqjROmbpwcMljoP1Rl0r9ifIVuYhuV_D6nCvy1T1_rl-bzfvL2_px03jBeW0iguJOBM6h9621NgrZ9gpdG7xGBCOlkkIpJ4UOToMXyjCIDEProwQNK3L7v7v_6UcM230eRpd_t-dv8AfIW0_5 |
CitedBy_id | crossref_primary_10_1089_jwh_1995_4_587 crossref_primary_10_1177_030089169708300623 crossref_primary_10_1023_A_1006490524736 |
ContentType | Journal Article |
DBID | CGR CUY CVF ECM EIF NPM |
DOI | 10.1007/BF01225692 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) |
DatabaseTitleList | MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | no_fulltext_linktorsrc |
Discipline | Medicine |
ExternalDocumentID | 7797604 |
Genre | Journal Article |
GroupedDBID | --- -53 -5E -5G -BR -EM -Y2 -~C -~X .55 .86 .GJ .VR 06C 06D 0R~ 0VY 199 1N0 1SB 2.D 203 28- 29K 29~ 2J2 2JN 2JY 2KG 2KM 2LR 2P1 2VQ 2~H 30V 36B 3O- 3V. 4.4 406 408 409 40D 40E 53G 5QI 5RE 5VS 67Z 6NX 78A 7X7 88E 8AO 8C1 8FI 8FJ 8G5 8UJ 95- 95. 95~ 96X AAAVM AABHQ AAEOY AAHNG AAIAL AAJKR AAKKN AANXM AANZL AARHV AARTL AATVU AAUYE AAWCG AAYIU AAYOK AAYQN AAYTO AAYZH ABAKF ABBBX ABBXA ABDZT ABECU ABEEZ ABFTV ABHLI ABHQN ABIPD ABJNI ABJOX ABKCH ABKTR ABLJU ABMNI ABMQK ABNWP ABPLI ABSXP ABTEG ABTKH ABTMW ABULA ABUWG ABWNU ABXPI ACACY ACBXY ACGFS ACHSB ACHVE ACHXU ACIPQ ACKNC ACMDZ ACMLO ACOKC ACOMO ACPRK ACUDM ACULB ACZOJ ADBBV ADHHG ADHIR ADINQ ADKNI ADKPE ADRFC ADTPH ADURQ ADYFF ADZKW AEBTG AEFIE AEFQL AEGAL AEGNC AEJHL AEJRE AEKMD AENEX AEOHA AEPYU AESKC AETLH AEVLU AEXYK AFBBN AFEXP AFFNX AFGXO AFKRA AFLOW AFQWF AFWTZ AFZKB AGAYW AGDGC AGGDS AGJBK AGMZJ AGQEE AGQMX AGRTI AGWIL AGWZB AGYKE AHAVH AHBYD AHIZS AHKAY AHMBA AHSBF AHYZX AIAKS AIIXL AILAN AITGF AJBLW AJOOF AJRNO AJZVZ AKMHD ALIPV ALMA_UNASSIGNED_HOLDINGS ALWAN AMKLP AMXSW AMYLF AMYQR AOCGG ARMRJ ASPBG AVWKF AXYYD AZFZN AZQEC B-. BA0 BBWZM BDATZ BENPR BGNMA BPHCQ BVXVI C24 C6C CAG CCPQU CGR COF CS3 CSCUP CUY CVF D-I DDRTE DL5 DNIVK DPUIP DU5 DWQXO EBD EBLON EBS ECM EIF EIOEI EJD EMB EMOBN EN4 ESBYG F5P FEDTE FERAY FFXSO FIGPU FINBP FNLPD FRRFC FSGXE FWDCC FYUFA G-Y G-Z GGCAI GGRSB GJIRD GNUQQ GNWQR GQ6 GQ7 GQ8 GRRUI GUQSH GXS H13 HF~ HG5 HG6 HMCUK HMJXF HQYDN HRMNR HVGLF HZ~ I09 IHE IJ- IKXTQ IMOTQ ITM IWAJR IXC IZIGR IZQ I~X I~Z J-C J0Z JBSCW JCJTX JZLTJ KDC KOV KOW KPH LAS LLZTM M1P M2O M4Y MA- N2Q N9A NB0 NDZJH NPM NPVJJ NQJWS NU0 O9- O93 O9G O9I O9J OAM OVD P19 P2P P9S PF0 PQQKQ PROAC PSQYO PT4 PT5 Q2X QOK QOR QOS R89 R9I RHV RIG RNI ROL RPX RRX RSV RZK S16 S1Z S26 S27 S28 S37 S3B SAP SCLPG SDE SDH SDM SHX SISQX SMD SNE SNPRN SNX SOHCF SOJ SPISZ SRMVM SSLCW SSXJD STPWE SV3 SZ9 SZN T13 T16 TEORI TSG TSK TSV TT1 TUC U2A U9L UG4 UKHRP UOJIU UTJUX UZXMN VC2 VFIZW W23 W48 WJK WK8 X7M YLTOR Z45 Z7U Z82 Z83 Z87 Z8O Z8V Z8W Z91 ZGI ZMTXR ZOVNA ZXP ~EX ~KM |
ID | FETCH-LOGICAL-c311t-fe251a3d112bc8999f348b5ea8dc6ee274454355a436da62c35702f0ed8cf4262 |
ISSN | 0171-5216 |
IngestDate | Wed Oct 16 00:49:52 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 6 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c311t-fe251a3d112bc8999f348b5ea8dc6ee274454355a436da62c35702f0ed8cf4262 |
PMID | 7797604 |
ParticipantIDs | pubmed_primary_7797604 |
PublicationCentury | 1900 |
PublicationDate | 1995-06-01 |
PublicationDateYYYYMMDD | 1995-06-01 |
PublicationDate_xml | – month: 06 year: 1995 text: 1995-06-01 day: 01 |
PublicationDecade | 1990 |
PublicationPlace | Germany |
PublicationPlace_xml | – name: Germany |
PublicationTitle | Journal of cancer research and clinical oncology |
PublicationTitleAlternate | J Cancer Res Clin Oncol |
PublicationYear | 1995 |
SSID | ssj0017572 |
Score | 1.4865626 |
Snippet | Formestane, a new selective aromatase inhibitor devoid of severe side-effects, has been shown to be active in patients with advanced breast cancer. To... |
SourceID | pubmed |
SourceType | Index Database |
StartPage | 378 |
SubjectTerms | 17-Hydroxycorticosteroids - urine Aged Androstenedione - administration & dosage Androstenedione - analogs & derivatives Androstenedione - therapeutic use Antineoplastic Agents - administration & dosage Antineoplastic Agents - therapeutic use Aromatase Inhibitors Breast Neoplasms - drug therapy Breast Neoplasms - metabolism Breast Neoplasms - pathology Drug Administration Schedule Estradiol - blood Female Humans Injections, Intramuscular Middle Aged Postmenopause Prognosis Risk Factors Survival Analysis Treatment Outcome |
Title | Formestane: an effective first-line endocrine treatment for advanced breast cancer |
URI | https://www.ncbi.nlm.nih.gov/pubmed/7797604 |
Volume | 121 |
hasFullText | |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Li9swEBbJlpZclr7CPtqiQ2_FJX7IsntrloZQ2BzKBkIvQY8RtBA7sN5Lfv2OHnacpC1tL8ZYIGzNp_En6ZsZQt4nBn8rErJIlQYi_B-LqNR5GjFlQDANULgUG7eLfL7Mvq7YajDY9aNLGvlR7X4ZV_I_VsVnaFcbJfsPlu06xQd4j_bFK1oYr39l4xkSTrD0zgWY40z16gyXyfsH0rrIcUiodK1skF9PVe60k-3xv7TC9Mbqv1TQ6p6yVd_4IeQGCuFwbVRlXamD3fnv6Go2sj446ZmKn9B4qtoFPyysrFvcq8Pt2unDble7SlNBzahDlB7bi6fafUoe4xrXh1F2jjaJe4jqu83Ul_E5ceeTVqQeo9vJfdG8nl23G2dYzpFT-SLGf2w8SqwdWoZkyAvrGxd2nyecP3Hmyn51n3GY2Da8zYg8DX0crUkcN7l7Ts6Dmehnj5AXZADVS_LsNsgmXpFve6B8oqKiHUzoHia0gwntYEIRJrSFCfUwoR4Jr8ly9uXuZh6FYhqRSuO4iQwgkxWpRn4tFS6yS5NmhWQgCq1yAJsokuFUZSJLcy3yRKWMTxIzAV0oY8sWjMlZVVdwQWhsSuDYE1LpMks4F4kUSiaFKUCrwsSXZOxHY731GVPWYZiuftdwTUZ7FL0hTwxOUHiLbK-R75xhHgFKLlWm |
link.rule.ids | 786 |
linkProvider | National Library of Medicine |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Formestane%3A+an+effective+first-line+endocrine+treatment+for+advanced+breast+cancer&rft.jtitle=Journal+of+cancer+research+and+clinical+oncology&rft.au=Zilembo%2C+N&rft.au=Bajetta%2C+E&rft.au=Noberasco%2C+C&rft.au=Buzzoni%2C+R&rft.date=1995-06-01&rft.issn=0171-5216&rft.volume=121&rft.issue=6&rft.spage=378&rft_id=info:doi/10.1007%2FBF01225692&rft_id=info%3Apmid%2F7797604&rft_id=info%3Apmid%2F7797604&rft.externalDocID=7797604 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0171-5216&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0171-5216&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0171-5216&client=summon |